Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia

Imatinib is the current standard of care in the treatment of chronic myeloid leukemia (CML), inducing durable responses and prolonged progression-free survival. However, plasma exposure to the drug from a given dosing regimen can vary widely among patients. Reasons for this may include incomplete ad...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2009-09, Vol.23 (9), p.1537-1544
Hauptverfasser:	Cortes, J E, Egorin, M J, Guilhot, F, Molimard, M, Mahon, F-X
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Benzamides Biological and medical sciences Blood Cancer Cancer Research Chronic myeloid leukemia Critical Care Medicine Decisions Diagnosis Dosage Drug dosages Drug interaction Drug Interactions Drug metabolism Drug therapy Hematologic and hematopoietic diseases Hematology Humans Imatinib Imatinib Mesylate Inhibitor drugs Intensive Internal Medicine Intestinal Absorption Kinases Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Medication Adherence Medicine Medicine & Public Health Myeloid leukemia Oncology Orosomucoid - metabolism Patients Pharmacodynamics Pharmacokinetics Pharmacology Piperazines - adverse effects Piperazines - pharmacokinetics Piperazines - therapeutic use Plasma Protein Binding Proteins Pyrimidines - adverse effects Pyrimidines - pharmacokinetics Pyrimidines - therapeutic use review Targeted cancer therapy Treatment Failure
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!